Nkarta CEO Paul Hastings at Endpoints' #BIO22 panel (J.T. MacMillan Photography for Endpoints News)
Nkarta trims headcount as it sets sights on autoimmune cell therapy
Nkarta will let go about 10% of its workforce as it focuses on applying off-the-shelf cell therapy to an autoimmune disease, it disclosed in an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
